GlaxoSmithKline Pharma Share Price

NSE: GLAXO
|
Pharmaceuticals

₹ 2,538.90

+₹2.60 (0.10%)
1D
Last updated 14 Oct, 2026, 15:59 IST

GlaxoSmithKline Pharma Share Price Today

As of 14 Oct 2026, GlaxoSmithKline Pharma share price is ₹2,538.90. The stock opened at ₹2,536.30, compared to its previous close of ₹2,536.30. During today's trading session, GlaxoSmithKline Pharma share price moved in the range of ₹2,502.00 to ₹2,548.30, with an average price of ₹2,525.15 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,088.10 and a high of ₹3,120.70. On the performance front, GlaxoSmithKline Pharma share price has increased by 5.06% over the last six months and is down 7.79% on a year-on-year basis.

₹2,502.00
0.10% up today
₹2,548.30
1D LOW
1D HIGH

GlaxoSmithKline Pharma Returns Calculator

Volume
41,627
Average traded price
₹2,527.86
Last traded time
03:59:53 14 Oct
Last traded quantity
1
Circuit
L
H
₹2,029.10
₹3,043.50
52-week
L
H
₹2,088.10
₹3,120.70
Mkt Cap Cr
42,927.49
P/E
40.19
P/B
18.93
ROA
24.7%
ROE
45.69%
ROCE
61.23%
Quick Ratio
1.77
EV/EBITDA
27.33
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Glaxosmi. Pharma has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Glaxosmi. Pharma appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Glaxosmi. Pharma earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0135.035.0811.19%13.74%17.33%2.3121.42
Divis Laboratories2,46,222.1184.1814.6914.6%15.32%19.56%3.556.81
Torrent Pharmaceuticals1,76,300.5081.7720.964.87%25.49%13.85%0.7538.3
Zydus Lifesciences1,12,817.6824.574.168.57%18.59%17.35%0.9115.07
Laurus Labs1,11,898.66101.6420.9110.38%16.77%16.14%0.6854.71
Cipla1,06,129.9632.023.127.92%11.27%14.95%2.517.97
Dr. Reddy's Laboratories1,03,471.1432.52.725.48%11.07%12.54%1.3516.27
Mankind Pharma99,089.5247.326.07.36%11.74%13.13%0.7426.02
Aurobindo Pharma96,836.1026.12.566.34%9.25%11.76%1.1512.57
Lupin89,628.8316.153.9914.47%23.76%24.88%1.429.46

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About GlaxoSmithKline Pharma

ISIN
INE159A01016
Sector Market Cap
₹ 42,927.49 Cr

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

GlaxoSmithKline Pharma Financial Highlights

  • Revenue: GlaxoSmithKline Pharma reported revenue of ₹3,967.03 crore in FY26 vs ₹3,895.14 crore in FY25. It showed an increase of 1.85% on a yearly basis.
  • Operating Profit: GlaxoSmithKline Pharma reported an operating profit of ₹1,406.01 crore in FY26 vs ₹1,259.88 crore in FY25. It showed an increase of 11.60% on a year-on-year basis.
  • Net Profit: GlaxoSmithKline Pharma reported a net profit of ₹1,035.98 crore in FY26 vs ₹927.58 crore in FY25. It showed an increase of 11.69% on a yearly basis.

GlaxoSmithKline Pharma Quarterly Result Highlights

  • GlaxoSmithKline Pharma reported revenue of ₹982.20 crore in Jun 2026, compared with ₹1,031.25 crore in Mar 2026, representing a decrease of 4.76% on a quarter-on-quarter (QoQ) basis.
  • GlaxoSmithKline Pharma reported an operating profit of ₹322.45 crore in Jun 2026, compared with ₹373.10 crore in Mar 2026, representing a decrease of 13.58% on a quarter-on-quarter (QoQ) basis.
  • GlaxoSmithKline Pharma reported a profit of ₹237.18 crore in Jun 2026, compared with ₹277.86 crore in Mar 2026, reflecting a decrease of 14.64% on a QoQ basis.
  • The earnings per share (EPS) of GlaxoSmithKline Pharma stood at ₹61.15 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
75.00%
FII
4.75%
Other DII
2.41%
Retail and other
11.77%
Mutual funds
6.07%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20254.64%
Mar 20264.62%
Jun 20264.79%
Sep 20264.75%
1 day
+0.19%
1 week
-7.94%
1 month
-10.33%
1 year
-7.79%
3 years
+66.02%
5 years
+71.70%
Day
Open / Close
Change %
13 Oct 26
₹2,525.10 / ₹2,536.30
+0.19%
12 Oct 26
₹2,530.10 / ₹2,531.50
-0.35%
09 Oct 26
₹2,534.40 / ₹2,540.30
+0.23%
08 Oct 26
₹2,634.00 / ₹2,534.40
-3.78%
Show more

GlaxoSmithKline Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹3,821.67₹3,749.21₹3,453.71₹3,251.72
Other Income₹145.36₹145.93₹122.59₹100.66
Total Revenue₹3,967.03₹3,895.14₹3,576.30₹3,352.38
Total Expenses₹2,581.65₹2,639.95₹2,616.50₹2,515.02
Profit Before Tax₹1,406.01₹1,259.88₹816.19₹836.40
Tax₹370.03₹332.30₹226.23₹228.76
Profit After Tax₹1,035.98₹927.58₹589.96₹607.64
EPS - Basic₹61.15₹54.76₹34.83₹36.05
EPS - Diluted₹61.15₹54.76₹34.83₹36.05

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹1,385.39₹1,255.19₹959.80₹841.49
Income before WC changes₹1,320.14₹1,186.78₹914.67₹801.49
Change in Assets₹55.14₹29.53-₹107.15₹51.14
Change in Liabilities-₹153.31₹155.30₹168.17-₹96.89
Change in WC-₹98.17₹184.83₹61.02-₹45.75
Cash flow from Operations₹903.30₹1,289.90₹582.02₹484.23
Cash flow from Investing₹396.98-₹45.80₹8.71₹807.85
Cash flow from Financing-₹737.08-₹769.42-₹561.50-₹1,543.32
Total Cash Flow₹563.20₹474.68₹29.23-₹251.25
Cash (Start of the year)₹538.85₹64.17₹34.94₹286.19
Cash (End of the year)₹1,102.05₹538.85₹64.17₹34.94

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹717.67₹698.18₹758.20₹832.32
Current Assets₹3,606.20₹3,409.88₹2,798.42₹2,494.26
Total Assets₹4,323.87₹4,108.07₹3,556.62₹3,326.58
Current Liabilities₹1,779.10₹1,905.15₹1,524.95₹1,326.37
Net Current Asset₹1,827.09₹1,504.73₹1,273.47₹1,167.89
Non-Current Liabilities₹277.35₹251.60₹254.03₹258.94
Equity Capital₹2,267.42₹1,951.31₹1,777.64₹1,741.27
Total Equity & Liabilities₹4,323.87₹4,108.07₹3,556.62₹3,326.58

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹3,790.20₹3,723.49₹3,407.25₹3,216.34
Other Income₹142.56₹142.56₹123.48₹101.51
Total Revenue₹3,932.76₹3,866.05₹3,530.73₹3,317.86
Total Expenses₹2,559.17₹2,622.31₹2,578.08₹2,484.50
Profit Before Tax₹1,376.23₹1,248.44₹809.04₹832.39
Tax₹364.40₹329.39₹224.35₹227.69
Profit After Tax₹1,011.82₹919.05₹584.69₹604.71
EPS - Basic₹59.59₹54.01₹34.51₹35.88
EPS - Diluted₹59.73₹54.24₹34.51₹35.88

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹1,373.59₹1,243.74₹952.65₹837.49
Income before WC changes₹1,308.77₹1,174.77₹906.51₹796.63
Change in Assets₹62.42₹22.37-₹100.82₹42.28
Change in Liabilities-₹169.67₹163.81₹165.37-₹81.30
Change in WC-₹107.25₹186.18₹64.55-₹39.02
Cash flow from Operations₹881.42₹1,280.03₹578.94₹487.94
Cash flow from Investing₹385.25-₹36.53₹14.97₹805.19
Cash flow from Financing-₹737.07-₹769.42-₹561.50-₹1,544.18
Total Cash Flow₹529.60₹474.07₹32.41-₹251.05
Cash (Start of the year)₹536.22₹62.15₹29.74₹280.79
Cash (End of the year)₹1,065.82₹536.22₹62.15₹29.74

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹731.79₹717.38₹781.96₹860.98
Current Assets₹3,543.12₹3,383.55₹2,765.84₹2,466.72
Total Assets₹4,274.91₹4,100.93₹3,547.80₹3,327.70
Current Liabilities₹1,757.11₹1,900.81₹1,510.94₹1,317.03
Net Current Asset₹1,786.01₹1,482.73₹1,254.90₹1,149.69
Non-Current Liabilities₹276.63₹250.89₹252.76₹257.67
Equity Capital₹2,241.17₹1,949.23₹1,784.09₹1,753.00
Total Equity & Liabilities₹4,274.91₹4,100.93₹3,547.80₹3,327.70
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
2538.9
1
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 1
Buy orders: 0%
Sell orders: 100%
Bearish
3
Neutral
2
Bullish
3
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
29.41
Bearish
ATR (14)
86.29
Neutral
STOCH(9,6)
15.61
Bullish
STOCH RSI (14)
3.38
Bullish
ADX(9)
29.69
Bearish
UO(9)
36.92
Neutral
ROC(12)
-10.35
Bearish
WillR(14)
-89.78
Bullish
Period
Simple value
Exponential vaue
5D
2555.3
2572.77
10D
2658.85
2639.11
20D
2752.85
2716.34
50D
2805.03
2735.09
100D
2583.91
2655.1
Volume trend — traded volume by day
14 Oct0L
13 Oct0L
12 Oct0L
9 Oct0L
8 Oct0L
7 Oct1L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
GlaxoSmithKline Pharma
Pharmaceuticals
Add Stock
Add Another

GlaxoSmithKline Pharma Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.